Safety Profiles: Clinical Evidence You Need to Know
Which Is Safer Wegovy or Mounjaro: Understanding the Key Differences
When evaluating which is safer Wegovy or Mounjaro, it's essential to understand their different mechanisms of action. Wegovy (semaglutide) is a GLP-1 receptor agonist that mimics a single natural hormone, whilst Mounjaro (tirzepatide) is a dual agonist targeting both GLP-1 and GIP receptors. This fundamental difference influences their safety profiles and side effect patterns. Both are prescription-only medicines that have undergone rigorous clinical testing, with safety data from thousands of patients worldwide. The choice between them often depends on individual tolerance, medical history, and specific clinical circumstances rather than one being universally "safer" than the other.
At EverydayMeds (GPhC #9012878), we ensure patients receive comprehensive information about both options during their clinical assessment. Our prescribers evaluate your medical history, current medications, and individual risk factors to determine which treatment may be more suitable. Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which is right for you based on your specific circumstances and safety considerations.
Pricing Transparency: Discount Codes FIRST40 and DOSE25 Applied
Understanding which is safer Wegovy or Mounjaro shouldn't be complicated by hidden costs or unclear pricing. At EverydayMeds, we offer transparent pricing for both treatments. Wegovy starts at £79.99 for the 0.25mg starter dose, with discount code FIRST40 applied at checkout for new customers. Returning customers can use code DOSE25 for the same competitive pricing. Our bundled options provide convenience for longer treatment periods, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, ensuring seamless progression through the initial titration phase.
Both treatments require the same careful dose escalation schedule, meaning the pricing structure reflects the clinical necessity of gradual increases. The 2.4mg maintenance dose of Wegovy is priced at £209.99, while our Ultimate Stability Trio provides three months of maintenance supply for £649.99. This transparent approach allows you to plan your treatment costs whilst focusing on the safety considerations that matter most for your individual circumstances.
Clinical Evidence: Which Is Safer Wegovy or Mounjaro in Trials?
The safety profiles of both treatments are well-established through comprehensive clinical trials. Wegovy's safety data comes primarily from the STEP trial programme, including STEP 1 which demonstrated the treatment's tolerability profile over 68 weeks (Wilding et al., NEJM, 2021). Most side effects were gastrointestinal and decreased over time as patients adjusted to treatment. The SELECT cardiovascular outcomes trial further reinforced Wegovy's safety profile whilst demonstrating additional cardiovascular benefits.
Mounjaro's safety data derives from the SURMOUNT clinical programme, showing a generally similar side effect profile to other GLP-1 treatments. Both treatments share common potential side effects including nausea, vomiting, and diarrhoea, typically most pronounced during the initial weeks. Neither treatment has shown significant safety concerns that would make one universally safer than the other, though individual patient responses can vary considerably.
How Wegovy Works: GLP-1 Mechanism and Safety Implications
Wegovy functions as a GLP-1 receptor agonist, mimicking the action of a natural hormone that regulates appetite and blood glucose levels. This mechanism helps reduce appetite and promotes feelings of fullness after smaller meals, supporting weight management alongside a reduced-calorie diet and increased physical activity. The treatment works on brain appetite centres, potentially reducing food cravings and helping patients maintain healthier eating patterns. Understanding this mechanism helps explain why gradual dose escalation is crucial for both efficacy and safety, allowing the body to adjust to the medication's effects. The once-weekly injection schedule using the FlexTouch pen system provides consistent therapeutic levels whilst minimising injection site reactions.
Ordering Process: Clinical Assessment to Cold-Chain Delivery
Determining which is safer Wegovy or Mounjaro for your specific situation begins with our comprehensive 3-minute online clinical assessment. This evaluation covers your medical history, current medications, previous weight loss attempts, and any contraindications to either treatment. Our qualified prescribers review each assessment thoroughly, typically within 3 working days (or 24 hours with express service), ensuring safety considerations are properly evaluated. Once approved, your chosen treatment is dispatched via next-day cold-chain delivery, maintaining the medication's integrity from our GPhC-registered pharmacy to your door. This process ensures both treatments reach you in optimal condition whilst meeting all regulatory requirements for prescription-only medicines.
Storage and Practical Considerations: Wegovy vs Mounjaro Flexibility
One practical safety advantage when considering which is safer Wegovy or Mounjaro relates to storage requirements and travel flexibility. Wegovy can remain at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day limit. This extended room temperature stability reduces the risk of medication degradation during travel or temporary storage issues. Both treatments require refrigeration at 2-8°C before first use and utilise similar injection pen technology. The longer room temperature tolerance of Wegovy provides additional peace of mind for patients who travel frequently or may experience temporary refrigeration issues, potentially reducing treatment interruptions that could affect safety and efficacy.
Individual Safety Profiles: Which Is Safer Wegovy or Mounjaro for You?
The question of which is safer Wegovy or Mounjaro cannot be answered universally, as safety depends on individual patient factors including medical history, current medications, and personal tolerance. Patients with certain gastrointestinal conditions may respond differently to each treatment's side effect profile. Those with a history of thyroid issues require careful evaluation, as both treatments carry specific warnings that must be considered during prescribing.
Some patients may find one treatment's side effect profile more tolerable than the other, even though both share similar overall safety characteristics. Our clinical team evaluates factors such as previous medication responses, family medical history, and concurrent health conditions to help determine which option may be more appropriate. This individualised approach ensures that safety considerations specific to your circumstances are properly addressed rather than relying on generalised comparisons.
Start Your Safety-First Treatment Today: Codes FIRST40 and DOSE25
Making an informed decision about which is safer Wegovy or Mounjaro starts with professional clinical assessment and transparent pricing. Use discount code FIRST40 at checkout if you're a new customer, or DOSE25 for returning patients, ensuring you receive competitive pricing from £79.99. Our comprehensive approach combines clinical expertise with practical support, helping you navigate both safety considerations and treatment logistics. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment today. Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which is right for you based on your individual safety profile and treatment goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
